Mechanistic insights into heart failure progression and therapeutic target discovery through plasma microRNA

David de Gonzalo-Calvo1, María C García-Hidalgo1, Shambhabi Chatterjee2

  • 1Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain; CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain.

Insights

Plasma microRNAs (miRNAs) like miR-21-5p, miR-24-3p, and miR-221-3p are linked to heart failure (HF) onset. These findings may lead to new HF prevention strategies.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Early identification of heart failure (HF) pathobiological mechanisms is crucial for developing preventive strategies.
  • Understanding molecular pathways driving HF pathogenesis is key to identifying therapeutic targets.

Purpose of the Study:

  • To profile plasma microRNAs (miRNAs) to elucidate molecular pathways in HF pathogenesis.
  • To identify potential therapeutic targets for HF by analyzing miRNA profiles.

Main Methods:

  • A multicenter study involving 799 elderly patients (HOMAGE cohort) was conducted.
  • Plasma miRNAs associated with incident HF were analyzed using RT-qPCR and machine learning.
  • Bioinformatic analyses explored miRNA targets, including functional enrichment and drug-gene interactions.

Main Results:

  • Four miRNAs (miR-21-5p, miR-24-3p, miR-132-3p, miR-221-3p) were significantly associated with incident HF.
  • miR-21-5p, miR-24-3p, and miR-221-3p were identified as key miRNAs linked to HF onset.
  • Enriched pathways included calcium homeostasis, cell proliferation, stress response, metabolic dysregulation, and neurohormonal activation. Five FDA-approved agonists for GABBR2 were identified.

Conclusions:

  • The identified miRNAs offer a basis for future longitudinal and mechanistic HF studies.
  • These findings may inform the development of novel strategies for HF prevention.
  • miRNA profiling provides insights into HF pathogenesis and potential therapeutic avenues.
Abstract

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
847
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
948